| Literature DB >> 32840492 |
Christopher A Martin1,2, David R Jenkins3, Jatinder S Minhas4, Laura J Gray5, Julian Tang3, Caroline Williams1,2, Shirley Sze4, Daniel Pan1,2, William Jones6, Raman Verma1,7,8, Scott Knapp9, Rupert Major5,10, Melanie Davies11,8, Nigel Brunskill4,10, Martin Wiselka1,2, Chris Brightling1,7,8, Kamlesh Khunti11,8,12, Pranab Haldar1,7,8, Manish Pareek1,2,8.
Abstract
BACKGROUND: Accumulating evidence indicates that COVID-19 causes adverse outcomes in ethnic minority groups. However, little is known about the impact of ethnicity and household size on acquiring infection with SARS-CoV-2.Entities:
Keywords: BAME; COVID-19; Ethnicity; Lockdown; SARS-CoV-2
Year: 2020 PMID: 32840492 PMCID: PMC7366113 DOI: 10.1016/j.eclinm.2020.100466
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Demographic characteristics of cohort by SARS-CoV-2 PCR status.
| Variable | Total ( | PCR Positive ( | PCR Negative ( |
|---|---|---|---|
| Age (years), median (IQR) | 64 (45 – 78) | 65 (51 – 78) | 64 (42 – 79) |
| Gender, n(%) | |||
| Female | 1979 (48.9%) | 433 (44.6%) | 1546 (50.2%) |
| Male | 2072 (51.2%) | 538 (55.4%) | 1534 (49.8%) |
| Ethnicity, n(%) | |||
| White Caucasian | 3067 (75.7%) | 612 (63.0%) | 2455 (79.7%) |
| South Asian | 710 (17.5%) | 266 (27.4%) | 444 (14.4%) |
| Black | 122 (3.0%) | 44 (4.5%) | 78 (2.5%) |
| Other | 152 (2.75%) | 49 (5.1%) | 103 (3.3%) |
| Index of Multiple Deprivation Decile, n(%) | |||
| 1 (most deprived) | 443 (10.9%) | 93 (9.6%) | 350 (11.4%) |
| 2 | 326 (8.1%) | 93 (9.6%) | 233 (7.6%) |
| 3 | 483 (11.9%) | 142 (14.6%) | 341 (11.1%) |
| 4 | 415 (10.2%) | 117 (12.1%) | 298 (9.7%) |
| 5 | 324 (8.0%) | 58 (6.0%) | 266 (8.6%) |
| 6 | 368 (9.1%) | 94 (9.7%) | 274 (8.9%) |
| 7 | 405 (10.0%) | 90 (9.3%) | 315 (10.2%) |
| 8 | 454 (11.2%) | 98 (10.1%) | 356 (11.6%) |
| 9 | 418 (10.3%) | 100 (10.3%) | 318 (10.3%) |
| 10 (least deprived) | 411 (10.2%) | 85 (8.8%) | 326 (10.6%) |
| Missing | 4 (0.1%) | 1 (0.1%) | 3 (0.1%) |
| Estimated household size, median (IQR) | 2.5 (2.1 – 3.0) | 2.6 (2.3 – 3.3) | 2.5 (2.1 – 2.9) |
| Missing, n(%) | 24 (0.6%) | 6 (0.6%) | 18 (0.6%) |
| Number of comorbidities, n(%) | |||
| 0 | 2318 (57.2%) | 482 (49.6%) | 1836 (59.6%) |
| 1 | 688 (17.0%) | 199 (20.5%) | 489 (15.9%) |
| ≥2 | 1045 (25.8%) | 290 (29.9%) | 755 (24.5%) |
| Type of comorbidity, n(%) | |||
| Hypertension | 963 (23.8%) | 277 (28.5%) | 686 (22.2%) |
| Diabetes | 495 (12.2%) | 167 (17.2%) | 328 (10.7%) |
| Other cardiovascular | 415 (10.2%) | 104 (10.7%) | 311 (10.1%) |
| Cerebrovascular | 180 (4.4%) | 52 (5.4%) | 128 (4.2%) |
| Respiratory | 556 (13.7%) | 133 (13.7%) | 423 (13.7%) |
| AKI on admission, n(%) | 508 (12.5%) | 172 (17.7%) | 336 (10.9%) |
| EWS on admission, median (IQR) | 2 (0 – 3) | 2 (1 – 4) | 1 (0 – 3) |
| Missing, n(%) | 68 (1.7%) | 20 (2.1%) | 48 (1.6%) |
Footnote: ‘Other cardiovascular’ comprises; pacemaker in situ, congenital cardiac failure, congestive heart failure, ischaemic heart disease, mitral valve disorder, left heart failure. ‘Respiratory’ comprises; chronic bronchitis, chronic obstructive lung disease, asthma, pulmonary emphysema. ‘Cerebrovascular’ comprises; cerebral haemorrhage, cerebral infarction, cerebrovascular accident, cerebrovascular disease, hemiplegia, subarachnoid haemorrhage.
Demographic, comorbidity and physiological characteristics of cohort by ethnicity.
| White Caucasian | South Asian | Black | Other | |
|---|---|---|---|---|
| Total | 3067 (75.7%) | 710 (17.5%) | 122 (3.0%) | 152 (3.8%) |
| Age (years), median (IQR) | 68 (49 – 80) | 57 (39 – 70) | 50.5 (37 – 64) | 37.5 (23 – 56) |
| Gender, n(%) | ||||
| Female | 1516 (49.4%) | 331 (46.6%) | 62 (50.8%) | 70 (46.1%) |
| Male | 1551 (50.6%) | 379 (53.4%) | 60 (49.2%) | 82 (54.0%) |
| Index of Multiple Deprivation Decile, n(%) | ||||
| 1 (most deprived) | 337 (11.0%) | 58 (8.2%) | 34 (27.9%) | 14 (9.2%) |
| 2 | 199 (6.5%) | 90 (12.7%) | 18 (14.8%) | 19 (12.5%) |
| 3 | 287 (9.4%) | 146 (20.6%) | 19 (15.6%) | 31 (20.4%) |
| 4 | 247 (8.1%) | 128 (18.0%) | 16 (13.1%) | 24 (15.8%) |
| 5 | 242 (7.9%) | 61 (8.6%) | 9 (7.4%) | 12 (7.9%) |
| 6 | 269 (8.8%) | 72 (10.1%) | 10 (8.2%) | 17 (11.2%) |
| 7 | 337 (11.0%) | 53 (7.5%) | 6 (4.9%) | 9 (5.9%) |
| 8 | 413 (13.5%) | 32 (4.5%) | 1 (0.8%) | 8 (5.3%) |
| 9 | 373 (12.2%) | 36 (5.1%) | 5 (4.1%) | 4 (2.6%) |
| 10 (least deprived) | 362 (11.8%) | 33 (4.7%) | 3 (2.5%) | 13 (8.6%) |
| missing | 1 (0.03%) | 1 (0.1%) | 1 (0.8%) | 1 (0.7%) |
| Estimated household size, median (IQR) | 2.4 (2.1 – 2.8) | 3.1 (2.6 – 3.6)* | 2.5 (2.00 – 3.00) | 2.7 (2.3 – 3.1) |
| Number of comorbidities, n(%) | ||||
| 0 | 1704 (55.6%) | 421 (59.3%) | 77 (63.1%) | 116 (76.3%)* |
| 1 | 533 (17.4%) | 114 (16.1%) | 20 (16.4%) | 21 (13.8%) |
| ≥2 | 830 (27.1%) | 175 (24.7%) | 25 (20.5%) | 15 (9.9%)* |
| Type of comorbidity, n(%) | ||||
| Hypertension | 760 (24.8%) | 165 (23.2%) | 25 (20.5%) | 13 (8.6%)* |
| Diabetes | 330 (10.8%) | 135 (19.0%)* | 20 (16.4%) | 10 (6.6%) |
| Other cardiovascular | 339 (11.1%) | 66 (9.3%) | 5 (4.1%) | 5 (3.3%)* |
| Cerebrovascular | 151 (4.9%) | 22 (3.1%)* | 4 (3.3%) | 3 (2.0%) |
| Respiratory | 469 (15.3%) | 65 (9.2%)* | 8 (6.6%) | 14 (9.2%)* |
| AKI on admission, n(%) | 387 (12.6%) | 93 (13.1%) | 17 (13.9%) | 11 (7.2%)* |
| EWS on admission, median (IQR) | 2 (0 – 3) | 2 (0 – 4) | 2 (1 – 4) | 1 (0 – 3) |
Footnote: ‘Other cardiovascular’ comprises; pacemaker in situ, congenital cardiac failure, congestive heart failure, ischaemic heart disease, mitral valve disorder and left heart failure. ‘Respiratory’ comprises; chronic bronchitis, chronic obstructive lung disease, asthma and pulmonary emphysema. ‘Cerebrovascular’ comprises; cerebral haemorrhage, cerebral infarction, cerebrovascular accident, cerebrovascular disease, hemiplegia and subarachnoid haemorrhage.
chi2 (for proportions) or Wilcoxon rank-sum (for continuous, non-parametric variables), p<0.05 as compared to White cohort.
Unadjusted and adjusted analysis of factors associated with SARS-CoV-2 PCR positivity.
| Age (years) | – | 1.01 (1.01 – 1.01) | <0.001 | 1.01 (1.01 – 1.01) | <0.001 |
| Gender | |||||
| Female | 433 / 1979 (21.9%) | – | – | – | – |
| Male | 538 / 2072 (26.0%) | 1.25 (1.08 – 1.45) | 0.002 | 1.21 (1.03 – 1.40) | 0.016 |
| Ethnicity | |||||
| White | 612 / 3067 (20.0%) | – | – | – | – |
| South Asian | 266 / 710 (37.5%) | 2.40 (2.02 – 2.87) | <0.001 | 2.44 (2.01 – 2.97) | <0.001 |
| Black | 44 / 122 (36.1%) | 2.26 (1.55 – 3.31) | <0.001 | 2.56 (1.71 – 3.84) | <0.001 |
| Other | 49 / 152 (32.2%) | 1.91 (1.34 – 2.71) | <0.001 | 2.53 (1.74 – 3.70) | <0.001 |
| IMD decile | |||||
| 1 (most deprived) | 92 / 443 (21.0%) | – | – | – | – |
| 2 | 93 / 326 (28.5%) | 1.50 (1.08 – 2.09) | 0.03 | 1.33 (0.93 – 1.88) | 0.12 |
| 3 | 142 / 483 (29.4%) | 1.57 (1.16 – 2.12) | 0.01 | 1.28 (0.93 – 1.76) | 0.13 |
| 4 | 117 / 415 (28.2%) | 1.48 (1.08 – 2.02) | 0.01 | 1.30 (0.93 – 1.81) | 0.12 |
| 5 | 58 / 324 (17.9%) | 0.82 (0.57 – 1.18) | 0.29 | 0.80 (0.55 – 1.17) | 0.25 |
| 6 | 94 / 368 (25.5%) | 1.29 (0.93 – 1.79) | 0.13 | 1.23 (0.87 – 1.73) | 0.24 |
| 7 | 90 / 405 (22.2%) | 1.08 (0.78 – 1.49) | 0.66 | 1.09 (0.77 – 1.54) | 0.63 |
| 8 | 98 / 454 (21.6%) | 1.04 (0.75 – 1.43) | 0.82 | 1.18 (0.84 – 1.65) | 0.34 |
| 9 | 100 / 418 (23.7%) | 1.18 (0.86 – 1.63) | 0.30 | 1.36 (0.97 – 1.91) | 0.07 |
| 10 (least deprived) | 85 / 411 (20.7%) | 0.98 (0.71 – 1.37) | 0.92 | 1.08 (0.76 – 1.53) | 0.66 |
| Estimated household size | – | 1.10 (1.05 – 1.15) | <0.001 | 1.06 (1.02 – 1.11) | 0.006 |
| Number of comorbidities | |||||
| 0 | 482 / 2318 (20.8%) | – | – | – | – |
| 1 | 199 / 688 (28.9%) | 1.55 (1.28 – 1.88) | <0.001 | 1.41 (1.11 – 1.79) | 0.005 |
| ≥2 | 290 / 1045 (27.8%) | 1.46 (1.24 – 1.73) | <0.001 | 1.23 (0.87 – 1.73) | 0.24 |
| Type of comorbidity | |||||
| Hypertension | 277 / 963 (28.8%) | 1.39 (1.18 – 1.64) | <0.001 | 0.96 (0.75 – 1.23) | 0.75 |
| Other cardiovascular | 104 / 415 (25.1%) | 1.07 (0.84 – 1.35) | 0.57 | 0.74 (0.56 – 0.98) | 0.04 |
| Diabetes | 167/495 (33.7%) | 1.74 (1.42 – 2.13) | <0.001 | 1.23 (0.95 – 1.60) | 0.11 |
| Cerebrovascular | 52/180 (28.9%) | 1.30 (0.94 – 1.82) | 0.12 | 1.05 (0.73 – 1.53) | 0.78 |
| Respiratory | 133/556 (23.9%) | 1.00 (0.81 – 1.23) | 0.98 | 0.86 (0.67 – 1.11) | 0.25 |
| AKI on admission | 172/508 (33.9%) | 1.76 (1.44 – 2.15) | <0.001 | 1.43 (1.15 – 1.77) | 0.001 |
| EWS on admission | – | 1.17 (1.14 – 1.20) | <0.001 | 1.14 (1.11 – 1.17) | <0.001 |
Footnote: ‘Other cardiovascular’ comprises; pacemaker in situ, congenital cardiac failure, congestive heart failure, ischaemic heart disease, mitral valve disorder and left heart failure. ‘Respiratory’ comprises; chronic bronchitis, chronic obstructive lung disease, asthma and pulmonary emphysema. ‘Cerebrovascular’ comprises; cerebral haemorrhage, cerebral infarction, cerebrovascular accident, cerebrovascular disease, hemiplegia and subarachnoid haemorrhage.
Fig. 1Temporal change in proportions of positive and negative swabs in each week over the timecourse of the study, stratified by ethnicity. Proportions of positive and negative tests per week of the study if total number of tests in that week exceeds 50. This excludes 1st March 2020 – 8th March 2020 (n = 22). Final week includes 27th and 28th April and represents a 9 day period.